Magnetic resonance lymphography

Current Opinion in Urology

Volumn 17, Issue 1, 2007, Pages 65-69

  Bellin, Marie France ^a   Roy, Catherine ^b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL CIVIL   (France)

Author keywords

Contrast enhancement; Lymph node; Lymphography; MRI; USPIO

Indexed keywords

BLADDER CANCER; CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHOGRAPHY; MAGNETIC RESONANCE LYMPHOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; REFERENCE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY; TESTIS CANCER;

DIAGNOSIS, DIFFERENTIAL; HUMANS; LYMPHATIC METASTASIS; LYMPHATIC SYSTEM; LYMPHOGRAPHY; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 33845452032     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32801198a3     Document Type: Review

References (17)

1. Oyen RH, Van Poppel HP, Ameye FE, et al. Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology 1994; 190:315-322.
2. Dooms GC, Hricak H, Crooks LE, et al. Magnetic resonance imaging of the lymph nodes: comparison with CT. Radiology 1984; 153:719-728.
3. Lee JKT, Heiken JP, Ling D, et al. Magnetic resonance imaging of abdominal and pelvic lymphadenopathy. Radiology 1984; 153:181-188.
4. Jager GJ, Barentsz JO, Oosterhof GO, et al. Pelvic lymphadenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional T1-weighted magnetization-prepared-rapid gradient-echo sequence. AJR 1996; 167:1503-1507.
5. Hricak H, Dooms GC, Jeffrey RB, et al. Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 1987; 162:331-336.
6. Davis GL. Sensitivity of frozen section examination of pelvic lymph node for metastatic prostate carcinoma. Cancer 1995; 76:661-666.
7. Salminen E, Hogg A, Binns D, et al. Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol 2002; 41:425-429.
8. Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990; 175:489-493.
9. Guimaraes R, Clement O, Bittoun J, et al. MR lymphography with superparamagnetic iron nanoparticles in rats: pathologic basis for contrast enhancement. AJR 1994; 162:201-207.
10. Bengele HH, Palmacci S, Rogers J, et al. Biodistribution of an ultrasmall superparamagnetic iron oxide colloid, BMS 18549, by different routes of administration. Magn Reson Imag 1994; 12:433-442.
11. Bellin MF, Roy C, Kinkel K, et al. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles. Initial clinical experience. Radiology 1998; 207:799-808.
12. Harisinghani MG, Saini S, Slater GJ, et al. MR imaging of pelvic lymph nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (Combidex): preliminary observations. JMRI 1997; 7:161-163.
13. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348:2491-2499.
14. Deserno WM, Harisinghani MG, Taupitz M, et al. Urinary bladder cancer: preoperative nodal staging with Ferumoxtran-10-enhanced MR imaging. Radiology 2004; 233:449-456.
15. Keller TM, Michel SCA, Frölich J, et al. USPIO-enhanced MRI for preoperative staging of gynecological pelvic tumors: preliminary results. Eur Radiol 2004; 14:937-944; Epub 2004 Feb 26.
16. Rockall AG, Sohaib SA, Harisinghani MG, et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 2005; 23:2813-2821. This study included 44 patients with endometrial (n = 15) or cervical (n = 29) cancer. Two independent observers viewed the MR images before lymph node sampling which was performed in all patients. On a patient-by-patient basis, the precontrast vs. postcontrast sensitivity was 27 vs. 100% with no loss of specificity. The kappa statistic was 0.93.
17. Harisinghani MG, Saksena M, Ross RW, et al. A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation. Urology 2005; 66:1066-1071. The study prospectively enrolled 18 patients with stage I testicular cancer. Nodal sampling was performed by CT-guided biopsy or laparoscopic surgery. The sensitivity and specificity of size criteria for detecting malignant nodes were 70.5 and 68%, respectively, while the sensitivity and specificity of MR lymphography were 88.2 and 92%, respectively.